[目的]观察口服美沙拉嗪联合锡类散保留灌肠治疗溃疡性结肠炎(UC)疗效。[方法]83例活动期UC患者随机分为2组,治疗组口服美沙拉嗪肠溶片1.0 g,4次/d,八味锡类散1.0 g加入0.9%氯化钠100 ml中,保留灌肠,1次/d;对照组口服美沙拉嗪肠溶片1.0 g,4次/d,疗程均为4周。比较2组的临床疗效及不良反应。[结果]2组患者治疗4周后症状明显改善,治疗组总有效率及临床治愈率分别为100%和95.0%,对照组分别为93.0%和74.4%。2组比较差异均有统计学意义(P<0.05),2组患者治疗后均未发现严重不良反应。[结论]美沙拉嗪口服联合锡类散保留灌肠治疗UC疗效显著。 [Objective] To observe the curative effect of oral mesalazine combined with tin-type retention enema in the treatment of ulcerative colitis (UC). [Method] Eighty-three active UC patients were randomly divided into two groups. The treatment group was given 1.0 g mesalazine enteric-coated tablets orally 4 times a day, and 0.8 g sodium stearate was added into 100 ml 0.9% sodium chloride Enema, 1 / d; the control group oral mesalazine enteric-coated tablets 1.0 g, 4 times / d, the course of treatment were 4 weeks. The clinical efficacy and adverse reactions of the two groups were compared. [Results] After 4 weeks of treatment, the symptoms of the two groups were significantly improved. The total effective rate and the clinical cure rate in the two groups were 100% and 95.0% respectively, while those in the control group were 93.0% and 74.4% respectively. The differences between the two groups were statistically significant (P <0.05). No serious adverse reactions were found in the two groups after treatment. [Conclusion] Mesalazine combined with tin-type retention enema in the treatment of UC has obvious curative effect.